Kite Pharma (KITE): CAR T Checks Show Physicians To Be Cautiously Optimistic - Jefferies

October 17, 2016 7:52 AM EDT
Get Alerts KITE Hot Sheet
Price: $45.91 -2.75%

Rating Summary:
    16 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade KITE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after attending the Lymphoma & Myeloma meeting where current treatment landscapes and future therapies that included CAR T were discussed.

The analyst believes physicians remain cautiously optimistic on CAR T therapies overall and are excited by the impressive data to date. Many physicians the analyst spoke with are looking forward to more mature data (e.g., durability data) to ultimately determine how CAR T fits into each indication's treatment landscape.

No change to the price target of $72.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $49.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment